The semisynthetic vitamin E derivative alpha-tocopheryloxyacetic acid (a-TEA) induces tumor cell apoptosis and may offer a simple adjuvant supplement for cancer therapy if its mechanisms can be better understood. Here we report that a-TEA also triggers tumor cell autophagy and that it improves cross-presentation of tumor antigens to the immune system. a-TEA stimulated both apoptosis and autophagy in murine mammary and lung cancer cells and inhibition of caspase-dependent apoptosis enhanced a-TEA-induced autophagy. Cell exposure to a-TEA generated double-membrane-bound vesicles indicative of autophagosomes, which efficiently crossprimed antigen-specific CD8 þ T cells. Notably, vaccination with dendritic cells pulsed with a-TEA-generated autophagosomes reduced lung metastases and increased the survival of tumor-bearing mice. Taken together, our findings suggest that both autophagy and apoptosis signaling programs are activated during a-TEA-induced tumor cell killing. We suggest that the ability of a-TEA to stimulate autophagy and enhance cross-priming of CD8 þ T cells might be exploited as an adjuvant strategy to improve stimulation of antitumor immune responses.
Introduction
Alpha-tocopheryloxyacetic acid (a-TEA) is a stable semisynthetic ether derivative of naturally occurring vitamin E (a-tocopherol). Although vitamin E has been pursued as an anticancer agent because of its antioxidant properties, the available epidemiologic data as well as in vivo studies in experimental animal tumor models have showed a limited role for vitamin E in cancer prevention or control (1-3) and may even be harmful as shown in the aborted SELECT clinical trial that examined the effect of high-dose vitamin E on prostate cancer (4) . a-TEA is derived from vitamin E by a chemical modification, which involves the replacement of the hydroxyl group at the number 6 carbon of the phenolic ring of the chroman head by an acetic acid residue linked by an ether bond (Supplementary Fig. S1 ; ref. 5) . This modification renders a-TEA, in contrast to vitamin E, redox silent but active against tumors of various origins (5) (6) (7) . The presence of a noncleavable ether bond ensures the stability of a-TEA, allowing it to be delivered via the oral route in a biologically active form. We reported for the first time that when incorporated into mouse chow, and supplied to mice in the diet, a-TEA significantly inhibited the growth of transplanted and spontaneously-arising metastatic breast cancers and dramatically reduced the incidence of spontaneous lung metastases before and after primary tumor establishment without overt toxicity (7, 8) .
Reports from numerous laboratories including our own have showed that apoptosis is a primary mode of a-TEA-induced tumor cell death (7) (8) (9) (10) , a process that is initiated by mitochondrial depolarization followed by release of cytochrome c to the cytosol and activation of the caspase execution pathway (reviewed in ref. 11 ). However, the observation that the antitumor activity of a-TEA cannot be completely blocked using pan or caspase-specific inhibitors (12, 13) suggests the involvement of additional pathway(s) in a-TEA-mediated tumor cell killing.
Autophagy is normally a protective survival mechanism used by cells undergoing various forms of stress, including chemotherapy, to sequester, process, and recycle damaged cellular organelles and misfolded and long-lived proteins to provide nutrients to the cell (reviewed in ref. 14) . It has recently become clear that apoptosis and autophagy are not mutually exclusive events (reviewed in ref. 15) and that both could lead to cell death (14, 16) . The formation of autophagosomes involves 3 major steps: The first (initiation stage) is the de novo formation of an isolation membrane, which is regulated by the mTOR and the Beclin-1 (Atg6)/class III phospohoinsitol-3 kinase (PI3K) complex. The second stage involves elongation and expansion of the phagophore to enclose cytosolic components including damaged organelles and misfolded proteins and requires the conjugation of Atg5 to Atg12. The final stage is the formation of a mature autophagosome ready for fusion with lysosomal vesicles, which requires conversion of soluble LC3-I (Atg8) to the membrane-bound form LC3-II (17) .
During autophagy, cellular components including viral or endogenous tumor-associated antigens (TAA) become available for cross-presentation by professional antigen-presenting cells (APC) to prime antigen-or tumor-specific T-cell responses (14, 18) . Although autophagy is known to play an essential role in major histocompatibility complex (MHC) class II-restricted antigen presentation (19) , only recently has its role in MHC class I-restricted stimulation of CD8 þ T cells (cross-presentation) become appreciated (18, 20) . In this study, we investigated whether a-TEA stimulates tumor cell autophagy and enhances antigen cross-presentation by dendritic cells (DC). We show that a-TEA induces tumor cell autophagy and that the a-TEA-derived autophagosome-enriched supernatant fraction (a-TAGS) stimulates efficient antigen cross-presentation. We describe here a novel mechanism of immune activation by a-TEA that involves the stimulation of tumor cell autophagy and enhanced crosspriming of CD8 þ T cells.
Materials and Methods
Preparation of a-TEA a-TEA [(2,5,7,8-tetramethyl-(2R-(4R,8R,12-trimethyltridecyl) chroman-6-yloxy) acetic acid)] was synthesized using a combination of previously described methods (2, 5) and vesiculated a-TEA (Va-TEA) was generated as previously described (8) .
Mice
Six-to 8-week-old female BALB/c and C57BL/6 mice were purchased from Harlan Laboratories. OT-I TCR transgenic breeders were purchased from the Jackson Laboratory. CT-TCR transgenic breeders were kindly provided by Dr. Jill E. Slansky (University of Colorado Denver School of Medicine, Denver, CO; ref. 21 ). All mice were maintained and used in accordance with the Principles of Animal Care (NIH publication No. 85-23) and all studies were approved by the EACRI Institutional Animal Care and Use Committee.
Tumor cell lines and cell culture
The poorly immunogenic and highly metastatic 4T1 tumor cell line was kindly provided by Dr. Fred Miller of the Michigan Cancer Foundation (Detroit, MI). The Lewis Lung carcinoma (3LL) cell line was kindly provided by Dr. Lea Eisenbach of the Weizmann Institute of Science (Rehovot, Israel).
DNA construction and transduction of cell lines
3LL or 4T1 tumor cells were transduced with lentiviral vectors that either expressed the ubiquitin-methionine green fluorescence protein-ovalbumin (Ub-M-GFP-OVA) antigen or LC3-GFP as previously described (18) . Ub-M-GFP-OVA antigen-or LC3-GFP-expressing cells were enriched for GFP positivity by fluorescence-activated cell sorting. LC3-GFP was transiently expressed in 3LL tumor cells after transfection using Lipofectamine-LTX (Invitrogen) following the manufacturer's instructions.
4T1 tumor cells stably transduced with Atg12-specific short hairpin RNA (shRNA; 4T1-Atg12shRNA) and scrambled (control) shRNA (4T1-CTRLshRNA) were generated previously. Atg12-specific shRNA expression is doxycycline-inducible and coexpressed with red fluorescent protein, which was monitored by epifluorescence. Atg12 gene knockdown was determined by Western immunoblotting. The transduced cells (4T1-LC3-GFP, 4T1-OVA-GFP, 4T1-Atg12shRNA, 4T1-CTRLshRNA, and 3LL-OVA-GFP) were maintained in culture medium containing 2 mg/mL puromycin (Sigma-Aldrich).
Quantification of LC3-GFP punctae
4T1-LC3-GFP or 3LL-LC3-GFP cells were cultured overnight on Lab-Tek II chamber slides (Thermo Fisher Scientific). The cells were then treated with Va-TEA or 100 mmol/L trehalose (Sigma-Aldrich) with the addition of 10 nmol/L bafilomycin-A1 (Sigma-Aldrich) for the last 2 hours of incubation. Cells were fixed and the fraction of punctate-positive cells per field of view was determined by counting punctate-positive and total number of cells in 12 to 30 random high-powered fields (Â100) of view per treatment by epifluorescence microscopy.
Apoptosis assay
Tumor cells were pretreated with 50 mmol/L zVAD-fmk (Sigma-Aldrich) for 2 hours before the addition of 40 mmol/L Va-TEA. Nonadherent and adherent cells were collected using 10 mmol/L EDTA, pooled and stained using the APC-Annexin-V/7AAD Apoptosis Detection Kit (BD Pharmingen) according to the manufacturer's instructions. Cells positively staining with APC-Annexin-V were considered to be apoptotic. , and 10 4 viable cells (trypan blue negative) from each treatment group were plated in triplicate (100 mm dishes) and incubated (7% CO 2 , 37 C) for 7 days. The resulting colonies were methanol-fixed, stained with Giemsa (Sigma-Aldrich), and counted. The surviving cell fraction was determined as previously described (7).
Generation and collection of a-TAGS
Tumor cells were treated with 20 mmol/L (4T1) or 80 mmol/L (3LL) Va-TEA for 24 hours. The culture supernatant was collected and cleared of dead cells and cell debris (300 Â g, 10 minutes). To obtain the autophagosome enriched fraction (a-TAGS), the supernatant containing the crude large vesicles was centrifuged at 10,000 Â g for 15 minutes. The a-TAGS pellet was resuspended in PBS and protein content was determined by bicinchoninic acid (BCA) protein assay (Thermo Scientific). For the control cells [vehicle (PBS)-treated] in which cells were not dying, culture medium was collected from twice as many cells. To block autophagy, cells were pretreated with 10 mmol/L 3-methyladenine (3-MA; Sigma-Aldrich) for 16 hours before a-TEA treatment.
Transmission electron microscopy a-TAGS was prepared from 4T1 or 3LL tumor cells treated with 20 or 80 mmol/L Va-TEA respectively, for 24 hours and prepared for transmission electron microscopy (TEM) as described in the Supplementary Methods. Microscopy was conducted at 60 kV on a Philips Morgagne TEM (FEI Inc.), equipped with a charge-coupled device camera and images were collected at original magnifications of Â1,000 to Â37,000.
Western blot analysis
To detect LC3 conversion, 3LL or 4T1 tumor cells were treated with 40 or 60 mmol/L Va-TEA or 400 nmol/L rapamycin (Sigma-Aldrich) for 16 hours with the addition of bafilomycin-A1 (Sigma-Aldrich) for the last 2 hours of culture. Cell lysates were prepared using Complete Lysis-M Buffer (Roche Applied Sciences) containing protease inhibitors. For in vivo LC3 conversion, 4T1 tumor-bearing mice received a-TEA in the diet ($6 mg/mouse/day) for 5 days. Subsequently, tumors were resected and lysed using CelLytic Mammalian Tissue Lysis Reagent (Sigma-Aldrich) containing protease inhibitors and a rotor-stator homogenizer. To detect Beclin-1 and cleavage of nuclear PARP, tumor cells were preincubated with zVAD-fmk (80 mmol/L) for 2 hours before treatment with a-TEA (80 mmol/L) for 16 hours. To detect Atg12, 4T1-Atg12shRNA and 4T1-CTRLshRNA were cultured with 2 mg/mL doxycycline for 72 hours before a-TEA treatment. All lysates were clarified (14,000 Â g, 15 minutes, 4 C) and protein content was determined by BCA (Thermo Scientific). After electrophoretic separation, proteins were detected by Western immunoblotting.
To detect endogenous LC3 in a-TAGS, a-TAGS was lysed in RIPA buffer and clarified. Protein content was determined by BCA (Thermo Scientific) and equal amounts (5 mg) of protein were electrophoretically separated and LC3 was detected by Western immunoblotting and quantified using Image-J software (22) .
Cross-presentation assay
For the in vitro cross-presentation assay, splenic DCs were generated as previously described (23) . OT-I splenocytes were carboxyfluorescein succinimidyl ester (CFSE)-labeled (5 mmol/L) and coincubated with antigen-loaded DCs (20 mg a-TAGS/1 Â 10 6 DC; 6 hours) in 10 mL tissue culture flat tubes (Techno Plastic Products AG) for 4 or 6 days. CFSE dilution was measured by flow cytometry as previously described (18) . To determine in vivo cross-presentation, a-TAGS (20 mg protein) was injected into both inguinal lymph nodes of naive C57BL/6 mice. On the same day, 3 Â 10 6 CFSElabeled Thy1.1 þ OT-I T cells were adoptively transferred by intravenous injection. Lymph nodes were collected 5 days later, and single-cell suspensions were prepared and CFSE dilution of Thy1.1 þ CD8 þ cells was determined by flow cytometry. Data were acquired and analyzed using BD CellQuest Pro software (BD Biosciences).
IFN-g ELISA 4T1-Atg12shRNA and 4T1-CTRLshRNA cells were incubated with 2 mg/mL doxycycline for 72 hours before preparation of a-TAGS as described earlier. DCs (3 Â 10 6 ) were pulsed with 20 mg a-TAGS for 6 hours, and washed 3 times. T cells (3 Â 10 6 ) isolated from CT-TCR mice were then coincubated with the DC for 48 hours and IFN-g secretion was detected by ELISA (eBioscience).
Generation of DCs and animal vaccination studies
For the 4T1 tumor model experiments, bone marrowderived DC (24) 
Statistical analysis
Statistical significance of differences among data sets was assessed by Student t test for pair wise comparisons or for comparisons of multiple groups by 1-way ANOVA with Tukey HSD test. Survival was assessed according to Kaplan and Meier including log-rank test. All analyses were done using Prism software (GraphPad). Probability values (P) of 0.05 were considered indicative of significant differences.
Results

a-TEA stimulates autophagy in tumor cells
To assess whether a-TEA stimulates autophagy in tumor cells, 3LL and murine mammary tumor (4T1) cells were treated with a-TEA and the levels of LC3-I and LC3-II were determined by Western immunoblotting. Induction of autophagy is associated with conversion of the cytosolic LC3-I to the membranebound LC3-II (17) . The data show that a-TEA induced a 7-fold increase in LC3-II conversion in a-TEA-treated 3LL tumor cells (Fig. 1A) . LC3-II conversion in a-TEA-treated 4T1 tumor cells was less robust and was $3-fold higher than vehicle (PBS)-treated cells (Fig. 1C) . As with a-TEA, 4T1 tumor cells were also less responsive than 3LL tumor cells to rapamycin, a known autophagy inducer. To confirm autophagy induction in a-TEA-treated tumor cells, we assessed the formation of LC3-GFP punctae in LC3-GFP transgene-expressing 3LL and 4T1 cells. a-TEA treatment caused a dose-dependent increase in LC3 punctae formation indicative of autophagy (25) in both 3LL (Fig. 1B) and 4T1 (Fig. 1D ) tumor cells. Punctae formation in a-TEA-treated 3LL cells was similar or higher than punctae formation induced by the known autophagy inducer trehalose (Fig. 1B) . a-TEA treatment of 4T1 cells also significantly increased punctae formation to levels comparable to trehalose (Fig. 1D) . To determine if a-TEA induces autophagy in vivo, 4T1 tumor-bearing animals received an oral dose of a-TEA (6 mg/day) that we have previously shown to reduce tumor growth and prolong survival (2, 7). LC3 conversion in the tumor was determined after 5 days of a-TEA treatment and we found approximately 3-fold increased LC3-II levels in 4T1 mammary tumors from a-TEA-treated mice compared with untreated mice (Fig. 1E) . Taken together, these 3 lines of evidence indicate that a-TEA induced autophagy in tumor cells.
Autophagy precedes apoptosis during a-TEA treatment On the basis of the documented property of a-TEA as a potent apoptosis-inducer (7, 8, 12, 13, 26) , we compared the kinetics of apoptosis and autophagy induction during a-TEA treatment. The data ( Fig. 2A and B) show that a-TEA-induced autophagy precedes apoptosis. At 4 hours of a-TEA treatment when no change in the percentage of apoptotic cells is observed compared with untreated cells (Fig. 2A) , the percentage of punctate-positive cells, indicative of autophagy is $25% (Fig. 2B) ; peak levels of apoptosis and autophagy are observed at 16 hours of a-TEA treatment. Our observation that a-TEA stimulates autophagy together with a recent report that treatment of stressed cells with the pan-caspase inhibitor zVADfmk enhanced autophagy (27, 28) , prompted us to evaluate the effect of apoptosis inhibition on a-TEA-induced autophagy. For this purpose, 4T1-LC3-GFP cells were treated with a-TEA in the presence of the pan-caspase inhibitor zVAD-fmk. a-TEA induced caspase-dependent apoptosis, which reached a maximum at 16 hours, was inhibited $55% by zVAD-fmk. In contrast, increase in the percentage of LC3-GFP punctatepositive cells, which was detected as early as 4 hours after a-TEA treatment (Fig. 2B) was enhanced by zVAD-fmk treatment. It has recently been reported that apoptosis induction may inhibit autophagy via regulation of Beclin-1 levels (27, 28) . Therefore, we determined Beclin-1 protein levels in a-TEAtreated tumor cells. The data (Fig. 2C) show a modest reduction in Beclin-1 protein in a-TEA-treated tumor cells compared with untreated cells (Fig. 2C) . Pretreatment with zVADfmk seems to restore Beclin-1 expression (Fig. 2C) .
a-TEA-induced autophagy decreases tumor cell survival
Because autophagy can either be protective or lead to tumor cell death (14, 29) , we assessed the impact of a-TEA treatment on tumor cell survival during autophagy inhibition. This was Effect of pan-caspase inhibition on a-TEA-induced tumor autophagy. A, 4T1-LC3-GFP cells were preincubated with the pan-caspase inhibitor zVADfmk for 2 hours and then treated with a-TEA for 4, 10, 16, or 24 hours in the presence of zVAD-fmk. Apoptosis was determined by flow cytometry after staining with 7-aminoactinomycin D (7-AAD) and Annexin-V-PE. B, 4T1-LC3-GFP cells were treated as in A, and formation of LC3-GFP punctae was determined by epifluorescence microscopy. Proportion of punctate-positive cells per field of view (magnification, Â100) was determined. Data are from 3 independent experiments. C, 4T1 tumor cells were treated with a-TEA for 10 or 16 hours in the presence of zVAD-fmk. PARP cleavage and Beclin-1 levels were determined by Western immunoblotting. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as loading control. Bar graphs indicate fold change of Beclin-1 (normalized to GAPDH) over untreated cells.
achieved by doxycycline-induced shRNA knockdown of the autophagy pathway gene, Atg12 (Fig. 3A) , which is essential for the membrane extension step that leads to autophagosomal vesicle formation (14) . Tumor cell survival was assessed using a long-term clonogenicity assay, which provides the most accurate assessment of cell death. a-TEA treatment concurrent with Atg12 knockdown significantly increased colony formation of a-TEA-treated cells (P > 0.0131), suggesting that autophagy contributed to a-TEA-mediated tumor cell death (Fig. 3B ).
a-TAGS is an efficient antigen carrier for cross-presentation
Given that we (18, 30) and others (19, 31) have previously shown that autophagy induction in tumor cells can play a pivotal role in cross-presentation of tumor-associated antigen, we hypothesized that a-TEA-generated autophagosomes augment antigen-specific CD8 þ T-cell activation. We first determined if a-TEA treatment of 4T1 and 3LL tumor cells resulted in release of autophagosomes. Examination of the precleared, high-speed (10,000 Â g) pellet fraction revealed the presence of double-membrane structures (Fig. 4A ) typical of autophagosomes (25) . In addition, immunoblot analysis showed that the autophagosome-enriched fraction (a-TAGS) contained elevated amounts of LC3-II (Fig. 4B) .
To determine whether a-TAGS is an antigen carrier and can stimulate cross-presentation to CD8 þ T cells, we pulsed DCs with a-TAGS collected from 3LL or 4T1 tumor cells that stably express the OVA protein and tested their ability to stimulate OVA-specific transgenic OT-I CD8 þ T cells (Fig. 5A ). DCs pulsed with a-TAGS from 3LL-OVA and 4T1-OVA cells stimulated vigorous OT-I CD8 þ T-cell proliferation with over 60% of T cells undergoing cell division (Fig. 5A and B) . In contrast, the equivalent high-speed fraction from a-TEA-treated parental 4T1 or 3LL tumor cells (data not shown) or untreated OVAexpressing (4T1-OVA, 3LL-OVA) cells did not significantly stimulate OT-I T-cell proliferation compared with unpulsed DC (Fig. 5B) . Furthermore, a-TAGS from OVA-expressing tumor cells stimulated proliferation of OT-I CD8 þ T cells in an a-TEA dose-dependent manner. Peak T-cell stimulation was achieved using 3LL-and 4T1-derived a-TAGS after treatment with 80 and 20 mmol/L a-TEA, respectively (data not shown). This finding suggests that a-TAGS is an efficient carrier of tumor antigens for cross-presentation.
Tumor cell autophagy plays an important role in a-TAGS activation of CD8 þ T cells
We next confirmed the role of autophagy in cross-presentation of a-TAGS by blocking tumor cell autophagy using 3-MA, which inhibits class III phosphoinositide 3-kinase (PI3K) required for initiation of autophagy. Inhibition of autophagy by 3-MA significantly inhibited OT-I CD8 þ T-cell activation by a-TAGS obtained from both 3LL and 4T1 tumor cells (Fig. 6A) . To further consolidate the role of autophagy in CD8 þ T-cell activation, a-TAGS was collected from doxycycline-treated 4T1-Atg12shRNA tumor cells in which the autophagy pathway was inhibited by RNA interference-mediated knockdown of Atg12. Activation of CT-TCR CD8 þ T that are specific for the AH1 peptide derived from the envelope (GP70) of an endogenous ecotropic murine leukemia virus in 4T1 tumor cells (21), by a-TAGS-pulsed DC was monitored by measuring IFN-g levels in the culture supernatant. Inhibition of autophagy by Atg12 gene knockdown dramatically diminished IFN-g production by CT-TCR CD8 þ T cells (Fig. 6B) . In contrast, CT-TCR CD8 þ T cells stimulated with DCs pulsed with a-TAGS isolated from cells expressing nonsilencing shRNA (4T1-CTRLshRNA) stimulated equivalent amounts of IFN-g in the absence or presence of doxycycline (Fig. 6B) .
Antitumor efficacy of a-TAGS-pulsed DC vaccination
Following our findings that a-TEA induces tumor cell autophagy and that autophagosomes derived from a-TEAtreated tumor cells are antigen carriers that stimulate crosspresentation in vitro, we wanted to first evaluate whether After 72-hour doxycycline incubation, Atg12 protein levels were determined by Western immunoblot detection of the Atg12-Atg5 complex using an Atg 12-specific antibody. B, the cells were then treated with a-TEA (60 mmol/L) for 24 hours. Nonadherent and adherent cells were collected, and the surviving fraction (SF) was determined after 7 days of culture without a-TEA. Mean SF AE SD from 4 independent experiments is shown. GAPDH, Glyceraldehyde-3-phosphate dehydrogenase.
a-TAGS can induce antigen-specific CD8 þ T-cell proliferation in vivo. We found that a-TAGS isolated from 3LL-OVA and 4T1-OVA cells that was injected into the inguinal lymph nodes of naive mice induced proliferation of over 90% and 50% of adoptively transferred OT-I CD8 þ T cells respectively, suggesting a-TAGS was efficiently cross-presented to CD8 þ T cells in vivo (Fig. 7A) . We next determined the impact of a-TAGSpulsed DC (a-TAGS-DC) vaccination on the growth of experimental 3LL lung metastases. Mice were injected intravenously with 3LL tumor cells, received a-TAGS-DC vaccinations 3 days later, and visible lung metastases were enumerated 28 day posttumor injection (Fig. 7B) . The results show that a-TAGS-DC vaccination significantly reduced the number of lung metastases $5-fold (P < 0.05) compared with no treatment (Control). Furthermore, the number of lung metastases in the a-TAGS-DC vaccination group was significantly lower (P < 0.05) compared with the DC alone (npDC), a-TAGS alone, or DC pulsed with freeze-thaw tumor cell lysate (Lysate-DC) groups. After these encouraging results, we wanted to determine if a-TAGS-DC vaccination is also efficacious against established tumors. For this purpose, 4T1 mammary tumorbearing mice received 3 subcutaneous a-TAGS-DC injections. The data (Fig. 7C) show that a-TAGS-DC treatment reduced the mean tumor size by 37% to 110 mm 2 from 175 mm 2 mean tumor size in untreated mice. Lysate-DC and a-TAGS vaccination resulted in 34% and 32% tumor size reduction, respectively; npDC vaccination had a minimal effect on tumor growth (148 mm 2 ). In addition, a-TAGS-DC treatment significantly (P < 0.05) prolonged the median survival to 37 days posttumor injection compared with 29 days median survival of control mice (Fig. 7D) . Injections of npDC or a-TAGS alone had no effect on survival (median survival in both groups was 31 days). Lysate-DC vaccination prolonged the median survival to 35 days.
Discussion
In this study, we investigated a-TEA-induced tumor cell autophagy and its role in the enhancement of the antitumor The cell culture supernatant was collected, and dead cells and debris were removed by centrifugation at 300 Â g for 10 minutes. Subsequently, the low-speed supernatant was centrifuged at 10,000 Â g for 15 minutes, and the high-speed pellet was examined by TEM. Double-membrane vesicles (arrows) with a variety of morphology were present. Their sizes ranged between 100 nm and 1 mm. Images were collected at original magnifications of Â1,000 to Â37,000. B, the high-speed fractions from untreated and a-TEA-treated 3LL or 4T1 cells were solubilized in lysis buffer, and equal amounts of protein (5 mg Figure 5 . a-TAGS stimulates cross-presentation. 3LL and 4T1 tumor cells that stably express the OVA peptide (3LL-OVA, 4T1-OVA) were treated with a-TEA, and the cell culture supernatant was subjected to centrifugal fractionation. The a-TEA-generated autophagosome-enriched supernatant fraction (a-TAGS) was resuspended in culture medium and pulsed onto DCs for 6 hours. The DCs were then washed and coincubated with CFSE-labeled OVA-specific TCR transgenic OT-I CD8 þ T cells.
Unpulsed DCs (no antigen) were included as controls. Proliferation of OT-I CD8 þ T cells was assessed by determination of CFSE dilution using flow immune response. We show for the first time that in addition to its well-described induction of tumor cell apoptosis, a-TEA induces autophagy in lung and mammary tumor cells and that autophagy-mediated cell death is partially responsible for the cytotoxic properties of a-TEA. Autophagy is considered a prosurvival mechanism for recycling damaged organelles and proteins by cells undergoing various forms of stress including nutrient deprivation. However, recent evidence suggests that under certain circumstances and depending on the stressor, extensive, and irreversible cellular damage can occur culminating in autophagic cell death (32, 33) . The contribution of autophagy to cell death has been documented in studies in which inhibition of the autophagy pathway genes, Atg5, Atg6, or Atg7 by RNAi resulted in increased cell survival (34) (35) (36) . Our finding that shRNA knockdown of Atg12 increased the clonogenicity of a-TEAtreated tumor cells is supportive of the role of autophagy in a-TEA-mediated tumor cell death.
Recently, it has become increasingly clear that autophagy and apoptosis are not independently regulated and that crosstalk may exist between both pathways (14, 15, 37) . The simultaneous induction of autophagy and apoptosis by a-TEA in our study has also been reported for other anticancer drugs including paclitaxel (38) , mitoxantrone (39) , oxaliplatin (39), melphalan (38) , arsenic trioxide (40) , imatinib (41) , and the proteasome inhibitor MG132 (42) . In our study, we found that autophagy preceded apoptosis during a-TEA treatment as has been previously reported for other stress triggers including growth factor starvation and apoptosis-inducing agents (27, 43) . However, unlike previous reports, which showed autophagy inhibition in association with progressive apoptosis (27, 43) , we showed that a-TEA-induced autophagy remained high over time. The finding in our study that blockade of apoptosis using the pan-caspase inhibitor, zVAD-fmk further increased the formation of LC3-II punctates in a-TEA-treated tumor cells, suggested cross-talk between both pathways during a-TEA-mediated tumor cell cytotoxicity. Interestingly, in our study, a-TEA treatment resulted in only a very modest decrease in Beclin-1 protein without detectable Beclin-1 cleavage products (data not shown). In the studies by Wirawan and colleagues (27) and Zhu and colleagues (43) where progressive apoptosis correlated with autophagy inhibition, caspasedependent cleavage of Beclin-1 was observed. The discrepancy between their findings and ours could be due, in part, to differences in the cell lines and stress triggers used in the studies. Our results suggest that autophagy and apoptosis induction by a-TEA occur in parallel and that Beclin-1 is likely not involved in regulation of cross-talk between both pathways.
We also show here for the first time that the autophagosome-enriched fraction (a-TAGS), generated by treating tumor cells in vitro with a-TEA, was an efficient tumor antigen carrier. DC pulsed with a-TAGS derived from OVA-expressing tumor cells stimulated antigen cross-presentation evidenced by enhanced proliferation of OVA-specific OT-I CD8 þ T cells. This CD8 þ T-cell activation could be partially blocked with 3-MA, suggesting that autophagy is essential for efficient antigen cross-presentation. Cross-presentation of an endogenous tumor-associated antigen (GP70) was also induced by a-TAGS and was inhibited by shRNA knockdown of Atg12, a gene product essential for autophagy. Thus, we show in our study by both pharmacologic and genetic inhibition of autophagy that a-TEA-induced autophagy is necessary for a-TAGSmediated stimulation of cross-presentation. The improved antigen cross-presentation by a-TAGS-pulsed DC (a-TAGS-DC) observed in vitro was also evident in vivo as intranodally injected a-TAGS derived from 3LL-OVA and 4T1-OVA tumor cells induced proliferation of adoptively transferred OT-I CD8 þ T cells, suggesting that a-TAGS-associated tumor antigens are cross-presented in vivo. More importantly, a-TAGS-DC vaccination was significantly more efficacious than tumor lysatepulsed DC (Lysate-DC) at reducing the incidence of experimental lung metastasis in the 3LL tumor model. a-TAGS-DC vaccination was less effective at suppressing established 4T1 tumors and its ability to prolong animal survival was comparable to that of Lysate-DC that have long been recognized to induce tumor-specific antitumor immune responses (44) . Taken together, these results suggest that tumor antigens in a-TAGS were cross-presented in vivo to stimulate an antitumor immune response. These results are also in agreement with our earlier report (2) showing that a-TEA treatment of tumor-bearing mice enhanced the antitumor immune response and resulted in increased cytokine secretion and tumor specific cytotoxicity and that the antitumor efficacy of a-TEA treatment was partially dependent on a functional T-cell response (2) . It has recently been reported that cytoreductive chemotherapeutics such as gemcitabine (45) and doxorubicin (46) can have immune-stimulatory effects and the emerging consensus is that these effects depend on the specific cytotoxic mechanisms of a given drug (47). Here we provide evidence for the first time that a-TEA induces tumor cell autophagy and that the autophagosome-enriched fraction stimulated tumor-specific cross-presentation that was dependent on a functional autophagy pathway. Because of its ability to stimulate autophagy and enhance cross-priming of CD8
þ T cells, a-TEA chemotherapy may have clinical relevance as a new strategy for generating tumor-associated antigens for cross-presentation by endogenous DC. Combining a-TEA therapy with immune modulators such as anti-CTLA-4, anti-OX40, or anti-4-1BB, which promote Tcell expansion, effector function, and survival could be an effective strategy for enhancing the antitumor response. , anti-programmed death ligand-1 (NCT00729664), anti-programmed death-1 (NCT00730639)] and could potentially be more effective when combined with a-TEA. Plans are underway at our institute to test the safety and tolerability of a-TEA in a first-in-human phase I trial in patients with advanced cancer.
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